In Abivax's trial, placebo patients dropped out due to lack of efficacy, meaning they were monitored for less time than patients on the effective drug. This "adverse event capture" bias can falsely make the drug arm appear to have a higher rate of side effects, a subtle but critical data interpretation error.

The stock fell dramatically despite blowout efficacy data because of a perceived cancer risk. A deeper dive shows this risk was overstated due to including non-cancers, common skin cancers, and failing to account for background cancer rates, creating a significant dislocation between price and fundamentals.

Management included raw cancer case numbers in their press release without proper framing or explanation. This led investors to perceive a problem that, upon expert review, wasn't there. This highlights the critical importance of communication strategy when releasing complex clinical data.

The speaker notes that despite publishing a mathematically-backed thesis showing Abivax's trial was guaranteed to succeed, the stock traded down. This demonstrates that even with clear, public data, the biotech market can be inefficient, rewarding investors who perform deep, fundamental analysis instead of following sentiment.

After the stock crashed on cancer fears, management accelerated the release of a larger safety dataset from October to June. This move, aimed at restoring confidence, suggests they believe the additional data will exonerate the drug, showing how companies must react dynamically to severe market misinterpretations.

Abivax's stock plunged 45% on a cancer signal in its ulcerative colitis trial, only to recover a significant portion of that loss. This volatility illustrates the market's initial overreaction and subsequent re-evaluation of a safety signal in a patient population already known to have a higher baseline risk of malignancy, highlighting the complexity of risk assessment.

Analysts largely overlooked Abivax before its major data success because it was a European company with a recent US listing, its drug was repurposed from an initial indication in HIV, and investor attention in the IBD space was focused on other high-profile mechanisms like TL1A and S1Ps.

A theoretical cardiac safety risk for Abivax's drug was first highlighted by competitor AbbVie at an investor conference. Analysts believe this risk is unlikely based on existing clinical data, suggesting such concerns can be a competitive tactic to cast doubt on a rival's asset rather than a significant clinical signal.

Abivax's stock plummeted despite best-in-class efficacy for its ulcerative colitis drug. Investors fixated on a few cancer cases deemed unrelated to the treatment, showing extreme risk aversion to new biological pathways where long-term safety is uncertain.